In the cell and gene therapy (CGT) industry, rapid and reliable clone selection after gene editing is critical to program success. Traditional methods often create bottlenecks with slow turnaround, limited throughput, and inconsistent accuracy in determining clonal purity and zygosity.
G-Screen℠ from GeneGoCell solves these challenges with high-throughput, cost-effective single cell clone genotyping powered by next-generation sequencing (NGS). As one of the core services in our Genome Editing Verification (GEV℠) suite, G-Screen℠ helps CGT developers, cell line engineers, and biopharmaceutical teams de-risk editing workflows, accelerate timelines, and generate regulatory-ready data.
The Challenge: Traditional Clone Screening Limitations
Gene editing projects in CGT and cell-based manufacturing frequently face extended screening timelines, high labor and reagent costs, and risks of mixed populations or ambiguous genotypes. These issues can delay IND-enabling work, increase development spend, and complicate documentation of clonal integrity. In a competitive landscape where speed to clinic and manufacturing consistency matter, inefficient clone genotyping directly impacts commercial outcomes.
G-Screen℠: Precision High-Throughput NGS for Gene-Edited Clones
G-Screen℠ enables accurate genotyping of insertions, deletions, substitutions, and other variants while determining population purity (pure vs. mixed) and zygosity (wild-type vs. heterozygous vs. homozygous). It processes thousands of clones in multi-well formats with minimal starting material, which is ideal for precious gene-edited cell populations in CGT pipelines.
Key Benefits of G-Screen for Cell Line Development
-
Fast Turnaround Time: Sample receipt to customized report typically in under 1 week (as fast as 3 days), compressing clone selection phases and shortening overall development timelines.
-
High Throughput & Low Sample Input: Genotype full 96-well plates starting from as few as 500 cells per well, supporting large-scale screening without excessive cell expansion.
-
High Accuracy & Data Quality: Robust NGS results deliver precise genotype calls and purity assessments essential for ensuring genetic stability and supporting regulatory submissions.
-
Significant Cost & Resource Savings: Reduces labor, reagents, and cell culture demands while offering competitive NGS pricing that improves project economics.
-
GxP-Compliant Quality: Processes aligned with compliant quality framework and standard, providing data suitable for highly regulated CGT and biopharma environments.
These advantages help teams optimize R&D ROI, reduce project risk, and gain a competitive edge in advancing differentiated therapies.
G-Screen Workflow: Efficient End-to-End Clone Genotyping
The G-Screen process is designed for simplicity and speed:
1. Client Site Workflow: Prepare and split cells at low confluence; ship frozen plates to GeneGoCell.
2. Sample Receipt: GeneGoCell receives samples and initiates processing.
3. High-Throughput NGS Genotyping & Analysis: Perform comprehensive sequencing and variant analysis.
4. Results Delivered: Receive detailed reports on ploidy, zygosity, variants, and annotations typically within one week.
This streamlined workflow minimizes your team’s hands-on time while delivering consistent, high-quality data for confident decision-making.
Case Study: G-Screen in Cas-CLOVER Gene Editing Evaluation in CHO Cells
A February 2026 publication in Biotechnology Progress, “Evaluation of gene editing in CHO cells using the Cas-CLOVER system,” demonstrates the value of advanced gene editing in CHO cells, which is a foundational platform for biologics production and many CGT-related manufacturing processes.
Researchers at Sanofi used G-Screen℠ to perform high-throughput, accurate single cell clone genotyping. This enabled precise characterization of editing outcomes, clonal purity, and zygosity, supporting confident selection and advancement of desired clones.
The study highlights how G-Screen integrates into sophisticated genome engineering programs, delivering the speed and data quality needed for robust cell line development in CGT and biopharma.
Read the publication on PubMed
Why GeneGoCell for Genome Editing Verification in CGT
GeneGoCell, based in San Diego, CA, specializes in customized, GxP/CLIA-compliant, ISO/IEC-accredited NGS and flow cytometry solutions tailored to CGT and genome editing needs.
G-Screen℠ works seamlessly with our broader GEV℠ portfolio, including G-Amp℠ for on- and off-target verification and G-GUIDE℠ (licensed GUIDE-seq service provider) for genome-wide off-target analysis, providing a true one-stop solution for comprehensive gene editing characterization. Our fast turnaround, expert project support, and focus on quality help clients move programs forward efficiently and compliantly.
Accelerate Your CGT Pipeline with G-Screen Today
Clone screening should accelerate, not delay, your development milestones. G-Screen℠ delivers the throughput, accuracy, and speed CGT and cell line engineering teams’ need to select high-quality clones with confidence while reducing time and cost.
Ready to optimize your clone selection strategy? Contact our team for a complimentary customized consultation with our SME. We’ll discuss how G-Screen can be tailored to your cell types, editing approach, and project goals.
Learn more about G-Screen℠ and our proprietary Genome-Editing Verification (GEV).
GeneGoCell: Compliant. Customized. Responsive. Fast. Let’s advance your gene editing and CGT programs together.